Where are you?
  • Austria
  • Belgium
  • Denmark
  • Finland
  • France
  • Germany
  • Guernsey
  • Ireland
  • Italy
  • Jersey
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Portugal
  • Spain
  • Singapore
  • Sweden
  • Switzerland
  • United Kingdom
  • Rest of World
It looks like you’re in
Not your location?
And finally, please confirm the following details
I’m {role} in {country} and I agree to comply with the terms of the website.
You are viewing as from Change

Liontrust SF UK Growth Fund

Q2 2024 review

Past performance does not predict future returns. You may get back less than you originally invested. Reference to specific securities is not intended as a recommendation to purchase or sell any investment.

The Fund returned 2.3% over the quarter, versus the IA UK All Companies sector average of 3.8% and the 3.6% return from the MSCI UK Index (both of which are comparator benchmarks)*.

The UK equity market enjoyed a strong quarter, as inflationary pressures receded, and the stability of a new government provided optimism for investors. The UK equity market outperformed its global equity peers for the first time in a number of quarters, and the relative performance of mid cap and cyclical sectors was more consistent. The UK equity market remains highly attractive in terms of its valuation, both compared to its developed market peers and to its own history. As the headwinds created through the political paralysis over the last few years come under control, as well as inflation, the UK equity market does provide significant opportunities and upside.

The Fund’s top performer for the quarter was investment company Molten Ventures. Held under our Enabling SMEs theme, Molten first saw its share price increase after US firm Hologic announced it had agreed to buy Endomagnetics, a medical technology company that Molten has been invested in since 2018. Shares also rose sharply in June on the release of full-year results in which the venture capital firm announced around £100 million of capital to be realized in 2025, with a minimum of 10% allocated to a share buyback. These actions underlined the attractive valuation opportunity as we were pleased to see this after significantly increasing the position early in the year.

Molten Ventures provides early-stage capital and backing for entrepreneurial companies linked to improving resource efficiency in industrial processes, increasing financial resilience, and innovation in healthcare. It tends to nurture companies until IPO or private sale at which point they realise their investment and recycle into new ventures.

Shares in UK bank NatWest rose after beating earnings estimates for Q1 as lending and deposits increased. Also held under our Enabling SMEs theme, NatWest reported pre-tax operating profit of £1.3 billion, compared with consensus estimates of £1.28 billion.

NatWest's corporate lending is focused on the areas that we view as being most beneficial to sustained economic growth, namely SME lending, leasing and factoring and traditional retail banking. It aims to reduce carbon within their corporate loan book by at least 50% by 2030 and has potentially interesting initiatives around mortgages for energy efficiency improvements in housing.

AstraZeneca, the pharmaceutical giant held under our Enabling innovation in healthcare theme, was also among the top performers as its shares surged after reporting profit that exceeded expectations, driven by demand for its cancer blockbusters Imfinzi and Tagrisso as well as its newly release drug, Enhertu. AstraZeneca’s Q1 sales were up by 19% to $12.7 billion, driven by an 18% increase in product sales and continued growth in alliance revenue from partnered medicines.

British gene and cell therapy specialist Oxford Biomedica is exposed to our Enabling innovation in healthcare theme. Having struggled over the last two years on concerns around de-stocking, it was pleasing to see Oxford Biomedica perform strongly following a ratings upgrade and the release of encouraging full year results. The leader in lentiviral vector innovation and manufacture reported that it is seeing solid demand for its contract development and manufacturing organisation offering, as it moves away from the Covid-19 vaccine era.

Among the Q1 detractors was money transfer platform Wise, which is held under our Transparency in financial markets theme. Wise's mission is to bring transparency and fairness to into moving money around the world. This covers pricing of products and sharing the economies of scale. Its mission is to bring FX costs down to zero. Revenue for Q4 23 came in 24% higher year-on-year at £277.2 million (not including interest income), taking the full-year figure to £1.05 billion, which was below average estimates. We remain optimistic about the company’s prospects despite the move.

Trainline, another detractor over the quarter, is a good example of a long-term holding progressing well operationally and financially but is out of favour as a UK smaller technology company. Held under our Making transport more efficient theme, Trainline’s technology platform is digitising rail and bus ticketing in the UK and Europe, enabling lower impact forms of transport by reducing friction for travellers and helping operators to manage capacity.

Since 2019, Trainline has grown revenues by 89% and has nearly doubled gross profit and adjusted EBITDA – however during this period the share price has disappointed. Trainline, in addition to generating healthy profit growth, has a robust balance sheet and continues to invest to further extend its competitive advantage. We believe the company is very attractively valued given the highly profitable business model and future growth prospects and we remain invested for the long-term despite the poor share price performance.

Shares in Convatec, the manufacturer of medical devices for people living and managing chronic disease held under our Enabling healthier lifestyles theme, fell after company flagged short-term uncertainty in Advanced Wound Care, leading to a softer outlook for the division.

In terms of trade activity, we added Sage Group under our Enabling SMEs theme. Sage provides accounting, payroll and HR solutions to SMEs that include 25% of employees in the UK. At any one time SMEs in the UK are owed an average of £22,000, so enabling them to keep track of their finances and meet regulatory standards increases the resilience of small businesses which are the anchor of the economy and employment.

We have watched the company for a number of years, and took the opportunity to open a position as the market was upset with slightly lower growth rates relative to the past. We believe this was an over-reaction and the company will still grow steadily over the long-term.

Intertek was sold after a long period of ownership. While we like the long-term structural drivers in increasing transparency and quality in supply chains, we believe that other companies in the portfolio offered a higher risk-adjusted reward with more effective asset allocation.

Distribution Finance Capital was sold to fund larger positions in Kainos and Gamma Communications – we believe these companies have stronger prospects and are less volatile larger companies.

Discrete years' performance (%) to previous quarter-end**:

 

Jun-24

Jun-23

Jun-22

Jun-21

Jun-20

Liontrust Sustainable Future UK Growth 2 Acc

12.1%

0.3%

-23.0%

28.7%

-4.5%

MSCI UK

13.1%

8.1%

9.2%

17.4%

-15.3%

IA UK All Companies

12.6%

6.2%

-8.5%

27.7%

-11.0%

Quartile

3

4

4

2

1


*
Source: FE Analytics, as at 30.06.24, total return, net of fees and income reinvested

** Source: FE Analytics, as at 30.06.24, primary share class, total return, net of fees and income reinvested

Understand common financial words and terms See our glossary
KEY RISKS

Past performance is not a guide to future performance. The value of an investment and the income generated from it can fall as well as rise and is not guaranteed. You may get back less than you originally invested.

The issue of units/shares in Liontrust Funds may be subject to an initial charge, which will have an impact on the realisable value of the investment, particularly in the short term. Investments should always be considered as long term.

All investments will be expected to conform to our social and environmental criteria. Overseas investments may carry a higher currency risk. They are valued by reference to their local currency which may move up or down when compared to the currency of the Fund. The Fund may encounter liquidity constraints from time to time. The spread between the price you buy and sell shares will reflect the less liquid nature of the underlying holdings. Outside of normal conditions, the Fund may hold higher levels of cash which may be deposited with several credit counterparties (e.g. international banks). A credit risk arises should one or more of these counterparties be unable to return the deposited cash. Counterparty Risk: any derivative contract, including FX hedging, may be at risk if the counterparty fails.

DISCLAIMER 

This is a marketing communication. Before making an investment, you should read the relevant Prospectus and the Key Investor Information Document (KIID), which provide full product details including investment charges and risks. These documents can be obtained, free of charge, from www.liontrust.co.uk or direct from Liontrust. Always research your own investments. If you are not a professional investor please consult a regulated financial adviser regarding the suitability of such an investment for you and your personal circumstances.

This should not be construed as advice for investment in any product or security mentioned, an offer to buy or sell units/shares of Funds mentioned, or a solicitation to purchase securities in any company or investment product. Examples of stocks are provided for general information only to demonstrate our investment philosophy. The investment being promoted is for units in a fund, not directly in the underlying assets. It contains information and analysis that is believed to be accurate at the time of publication, but is subject to change without notice. Whilst care has been taken in compiling the content of this document, no representation or warranty, express or implied, is made by Liontrust as to its accuracy or completeness, including for external sources (which may have been used) which have not been verified. It should not be copied, forwarded, reproduced, divulged or otherwise distributed in any form whether by way of fax, email, oral or otherwise, in whole or in part without the express and prior written consent of Liontrust.

Commentaries Sustainable Fixed Income

Related commentaries

See all related
Fund updates
Liontrust SF UK Growth Fund Q2 2024 review
icon 22 July 2024
Commentaries Sustainable Equity
Fund updates
Liontrust Sustainable Future Conclusion Outlook May 2024 video update
icon 28 May 2024
Sustainable Future (SF)
Fund updates
Liontrust Sustainable Future UK Equity Strategies May 2024 video update
icon 23 May 2024
Sustainable Future (SF)
Fund updates
Liontrust Sustainable Future Funds May 2024 video update
icon 23 May 2024
Sustainable Future (SF)
Fund updates
Liontrust SF UK Growth Fund Q1 2024 review
icon 26 April 2024
Commentaries Sustainable Equity
Peter Michaelis Peter Michaelis
Sustainable Future: Overview of Performance 2023 review
icon 7 February 2024
Peter Michaelis

Register your preferences and receive tailored communications from Liontrust